Evidence map›Paper›PMID 29422061›Full record

ArticleBMC pulmonary medicine2018

N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.

Justin M Oldham, Leah J Witt, Ayodeji Adegunsoye, Jonathan H Chung, Cathryn Lee, Scully Hsu, Lena W Chen, Aliya Husain, Steven Montner, Rekha Vij and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Redox Pathogenesis in Rheumatic Diseases.ACR open rheumatology · 2024
    Review
  4. Article
  5. Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects.American journal of respiratory and critical care medicine · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Justin M OldhamDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, The University of California at Davis, Sacramento, CA, USA. joldham@ucdavis.edu.
Leah J WittDepartment of Medicine; Division of Geriatrics, University of California at San Francisco, San Francisco, USA.
Ayodeji AdegunsoyeDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Jonathan H ChungDepartment of Radiology, The University of Chicago, Chicago, USA.
Cathryn LeeDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Scully HsuDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Lena W ChenDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Aliya HusainDepartment of Pathology, The University of Chicago, Chicago, USA.
Steven MontnerDepartment of Radiology, The University of Chicago, Chicago, USA.
Rekha VijDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Mary E StrekDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
Imre NothDepartment of Medicine; Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, USA.
University of Chicago · USUniversity of California, Davis · USUniversity of San Francisco · US

Funding

RESEARCH TRAINING IN RESPIRATORY BIOLOGYT32HL007605 · NHLBI · UNIVERSITY OF CHICAGO · PI Yun Fang, Gokhan M. Mutlu · 1985 to 2026
$18.1M
Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
National Heart, Lung, and Blood Institute (US) K23HL138190NHLBI NIH HHS K23 HL138190NHLBI NIH HHS T32 HL007605
6 · The paper itself

Abstract

backgroundMortality is similarly high among individuals with usual interstitial pneumonia (UIP) due to idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF). Circulating anti-nuclear antibodies (ANA) are commonly found in this patient population, suggesting possible aberrant immune activation. Because an environment of oxidative stress can result from immunologic activation, we hypothesized that ANA positive patients with UIP would have improved outcome when exposed to the antioxidant N-acetylcysteine (NAC) compared to ANA negative patients.

methodsA single center, retrospective cohort analysis was performed. Patients with UIP due to IPF and IPAF were stratified according to ANA status to and NAC exposure. Transplant-free survival (TFS) was assessed using the Kaplan-Meier estimator and multivariable Cox regression adjusted for diagnosis, gender/age/physiology score, immunosuppressant exposure and anti-fibrotic exposure.

resultsOf 293 individuals with UIP due to IPF (74%) or IPAF (26%), NAC exposure was documented in 58 (19.8%). Among NAC exposed individuals, 33 (56.9%) were ANA seropositive and 25 (43.1%) were seronegative. NAC exposure was associated with improved TFS survival among ANA seropositive individuals in unadjusted analysis (p

conclusionNAC exposure is associated with improved transplant-free survival ANA positive patients with UIP. These findings support the prospective collection of ANA data in in future NAC clinical trials performed in patients with UIP.

Indexed as

AcetylcysteineAgedAntibodies, AntinuclearCohort StudiesFemaleFree Radical ScavengersHumansIdiopathic Pulmonary FibrosisKaplan-Meier EstimateLung TransplantationMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRetrospective StudiesSurvival RateAcetylcysteineAntibodies, AntinuclearFree Radical ScavengersAnti-nuclear autoantibodyIdiopathic pulmonary fibrosisInterstitial lung diseaseInterstitial pneumonia with autoimmune features

Identifiers

PMID29422061
PMCPMC5806226
OpenAlexW2794795983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.